These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36386040)

  • 1. Outcomes of patients undergoing lung resection for drug-resistant TB and the prognostic significance of pre-operative positron emission tomography/computed tomography (PET/CT) in predicting treatment failure.
    Calligaro GL; Singh N; Pennel TC; Steyn R; Brink A; Esmail A; Mottay L; Oelofse S; Mastrapa BL; Basera W; Manning K; Ofoegbu C; Linegar A; Dheda K
    EClinicalMedicine; 2023 Jan; 55():101728. PubMed ID: 36386040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
    Olayanju O; Esmail A; Limberis J; Dheda K
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
    Borisov SE; D'Ambrosio L; Centis R; Tiberi S; Dheda K; Alffenaar JW; Amale R; Belilowski E; Bruchfeld J; Canneto B; Denholm J; Duarte R; Esmail A; Filippov A; Davies Forsman L; Gaga M; Ganatra S; Igorevna GA; Lazaro Mastrapa B; Manfrin V; Manga S; Maryandyshev A; Massard G; González Montaner P; Mullerpattan J; Palmero DJ; Pontarelli A; Papavasileiou A; Pontali E; Romero Leyet R; Spanevello A; Udwadia ZF; Viggiani P; Visca D; Sotgiu G; Migliori GB
    J Infect; 2019 Jan; 78(1):35-39. PubMed ID: 30096332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.
    Olayanju O; Limberis J; Esmail A; Oelofse S; Gina P; Pietersen E; Fadul M; Warren R; Dheda K
    Eur Respir J; 2018 May; 51(5):. PubMed ID: 29700106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective review comparing treatment outcomes of adjuvant lung resection for drug-resistant tuberculosis in patients with and without human immunodeficiency virus co-infection.
    Alexander GR; Biccard B
    Eur J Cardiothorac Surg; 2016 Mar; 49(3):823-8. PubMed ID: 26142471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the Novel Anti-TB Bedaquiline against Drug-Resistant TB in Africa: A Systematic Review of the Literature.
    Traoré AN; Rikhotso MC; Banda NT; Mashilo MS; Ngandu JPK; Mavumengwana V; Loxton AG; Kinnear C; Potgieter N; Heysell S; Warren R
    Pathogens; 2022 Jun; 11(6):. PubMed ID: 35745490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 10. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequential
    Bomanji J; Sharma R; Mittal BR; Gambhir S; Qureshy A; Begum SMF; Paez D; Sathekge M; Vorster M; Sobic Saranovic D; Pusuwan P; Mann V; Vinjamuri S; Zumla A; Pascual TNB
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3118-3129. PubMed ID: 32483653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis.
    Wu Y; Zhang Y; Wang Y; Wei J; Wang W; Duan W; Tian Y; Ren M; Li Z; Wang W; Zhang T; Wu H; Huang X
    Pharmacol Res; 2022 Aug; 182():106336. PubMed ID: 35779814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review.
    Singh L; Mathibe LJ; Bangalee V
    Health SA; 2021; 26():1708. PubMed ID: 34917407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
    Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
    BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
    Bionghi N; Daftary A; Maharaj B; Msibi Z; Amico KR; Friedland G; Orrell C; Padayatchi N; O'Donnell MR
    BMC Infect Dis; 2018 Apr; 18(1):171. PubMed ID: 29642874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis.
    Man MA; Nicolau D
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):e9-12. PubMed ID: 22531273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of drug-resistant TB in patients with HIV co-infection.
    Meintjes G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19508. PubMed ID: 25394017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.